The malaria drug is quickly falling out of favor with the medical community as a potential treatment for the disease. On the back of mounting concerns about hydroxychloroquine's safety, global pharmaceutical major Sanofi (NASDAQ:SNY) has quit providing it to COVID-19 patients enrolled in its clinical trials for the drug. It has also put a temporary…
A box of Plaquenil, an anti-malaria drug hydroxychloroquine made by Sanofi, used for years to treat malaria and autoimmune disorders.Alain Pitton | NurPhoto | Getty ImagesFrench drugmaker Sanofi said Friday it is suspending recruitment of new patients for its clinical trials looking at anti-malaria drug hydroxychloroquine as a potential treatment for the coronavirus.The company is also…
Please complete security verification This request seems a bit unusual, so we need to confirm that you're human. Please press and hold the button until it turns completely green. Thank you for your cooperation! Press and hold the button If you believe this is an error, please contact our support team. 185.149.70.50 : 71e764bb-7864-4240-8a67-bd0f9c05
You don't have permission to access "http://www.medpagetoday.com/publichealthpolicy/healthpolicy/117676" on this server. Reference #18.4ad7ce17.1758956517.d41a53ef https://errors.edgesuite.net/18.4ad7ce17.1758956517.d41a53ef
Most of us spend most of our gym time dead-set on blasting our biceps and torching our triceps, but fail to place any focus on our forearms. Sure, we may bang out a few sets of hammer curls every other workout and consider that a heavy-hitting forearm day. But aesthetics aren't the only downside of